CL2017001275A1 - Análogos ligados de urea sustituidos como moduladores de sirtuina - Google Patents

Análogos ligados de urea sustituidos como moduladores de sirtuina

Info

Publication number
CL2017001275A1
CL2017001275A1 CL2017001275A CL2017001275A CL2017001275A1 CL 2017001275 A1 CL2017001275 A1 CL 2017001275A1 CL 2017001275 A CL2017001275 A CL 2017001275A CL 2017001275 A CL2017001275 A CL 2017001275A CL 2017001275 A1 CL2017001275 A1 CL 2017001275A1
Authority
CL
Chile
Prior art keywords
disorders
diseases
sirtuin modulators
analogs substituted
modulators
Prior art date
Application number
CL2017001275A
Other languages
English (en)
Spanish (es)
Inventor
James Lamond Ellis
Karen Anderson Evans
Ryan Michael Fox
William Henry Miller
Mark Andrew Seefeld
Original Assignee
Glaxosmithkline Intellectual Property N 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property N 2 Ltd filed Critical Glaxosmithkline Intellectual Property N 2 Ltd
Publication of CL2017001275A1 publication Critical patent/CL2017001275A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2017001275A 2014-11-19 2017-05-18 Análogos ligados de urea sustituidos como moduladores de sirtuina CL2017001275A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462081916P 2014-11-19 2014-11-19

Publications (1)

Publication Number Publication Date
CL2017001275A1 true CL2017001275A1 (es) 2017-12-15

Family

ID=54705247

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001275A CL2017001275A1 (es) 2014-11-19 2017-05-18 Análogos ligados de urea sustituidos como moduladores de sirtuina

Country Status (21)

Country Link
US (4) US20170355705A1 (enExample)
EP (4) EP3221317B1 (enExample)
JP (4) JP2017534663A (enExample)
KR (4) KR20170087907A (enExample)
CN (4) CN107207520A (enExample)
AU (4) AU2015348944A1 (enExample)
BR (4) BR112017010602A2 (enExample)
CA (4) CA2968032A1 (enExample)
CL (1) CL2017001275A1 (enExample)
CO (1) CO2017004994A2 (enExample)
CR (1) CR20170209A (enExample)
DO (1) DOP2017000123A (enExample)
EA (1) EA201791074A1 (enExample)
ES (1) ES2823748T3 (enExample)
IL (1) IL252252A0 (enExample)
MX (1) MX2017006658A (enExample)
PE (1) PE20171257A1 (enExample)
PH (1) PH12017500913A1 (enExample)
RU (3) RU2017120855A (enExample)
SG (1) SG11201703824QA (enExample)
WO (4) WO2016079712A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016086088A2 (en) 2014-11-25 2016-06-02 Northwestern University Wound healing through sirt1 overexpression
CN108329388A (zh) * 2018-01-18 2018-07-27 天津市湖滨盘古基因科学发展有限公司 一种人的沉默配型信息调节蛋白突变蛋白及其应用
CN108707150B (zh) * 2018-05-14 2021-04-16 江苏惠利生物科技有限公司 一种咪唑并吡嗪医药中间体的制备方法
CN108395436B (zh) * 2018-05-14 2021-01-12 鹤壁市人民医院 一种咪唑并吡嗪医药中间体的制备方法
CN110478339A (zh) * 2019-08-12 2019-11-22 昆明理工大学 紫铆因在制备靶向恢复突变p53构象药物中的应用
EP4025566A1 (de) * 2019-09-02 2022-07-13 Merck Patent GmbH Materialien für organische elektrolumineszenzvorrichtungen
BR112022009649A2 (pt) * 2019-11-19 2022-08-16 Lupin Ltd Processo, intermediários e métodos para preparar compostos de cromano
FI4090654T3 (fi) * 2020-01-17 2025-09-30 Lupin Ltd Menetelmiä, prosesseja ja välituotteita kromaaniyhdisteiden valmistamiseksi
CN114890955A (zh) * 2022-06-23 2022-08-12 江西瑞威尔生物科技有限公司 一种n取代吗啉类有机化合物的制备工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO2006094210A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Tetrahydroquinoxalinone sirtuin modulators
UA108596C2 (xx) 2007-11-09 2015-05-25 Інгібітори пептиддеформілази
CA2779303A1 (en) * 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators
AU2012352442A1 (en) * 2011-12-12 2014-07-03 Smb Innovation Aps Novel heterocyclic compounds useful in sirtuin binding and modulation
WO2014186313A1 (en) * 2013-05-13 2014-11-20 Glaxosmithkline Llc Substituted bridged urea analogs as sirtuin modulators

Also Published As

Publication number Publication date
CA2968030A1 (en) 2016-05-26
WO2016079709A1 (en) 2016-05-26
BR112017010601A2 (pt) 2017-12-26
RU2017120857A (ru) 2018-12-19
CN107108627A (zh) 2017-08-29
JP6806679B2 (ja) 2021-01-06
BR112017010595A2 (pt) 2018-01-02
EP3221317B1 (en) 2020-07-22
US20190048016A1 (en) 2019-02-14
WO2016079711A1 (en) 2016-05-26
DOP2017000123A (es) 2017-08-15
AU2015348944A1 (en) 2017-06-01
KR20170087907A (ko) 2017-07-31
CA2968027A1 (en) 2016-05-26
CA2968029A1 (en) 2016-05-26
US20170355705A1 (en) 2017-12-14
RU2017120855A (ru) 2018-12-19
CN107207509B (zh) 2020-04-21
AU2015348942B2 (en) 2018-07-05
PE20171257A1 (es) 2017-08-28
CO2017004994A2 (es) 2017-09-20
RU2017120858A (ru) 2018-12-19
EP3221322A1 (en) 2017-09-27
US10072011B2 (en) 2018-09-11
MX2017006658A (es) 2018-01-15
JP2017534665A (ja) 2017-11-24
CR20170209A (es) 2017-07-17
CN107207520A (zh) 2017-09-26
WO2016079712A1 (en) 2016-05-26
AU2015348942A1 (en) 2017-06-01
EP3220918A1 (en) 2017-09-27
ES2823748T3 (es) 2021-05-10
EP3221317A1 (en) 2017-09-27
CN107207509A (zh) 2017-09-26
KR20170083133A (ko) 2017-07-17
IL252252A0 (en) 2017-07-31
US20170362234A1 (en) 2017-12-21
KR20170083135A (ko) 2017-07-17
JP2017534664A (ja) 2017-11-24
PH12017500913A1 (en) 2017-12-04
JP2017534662A (ja) 2017-11-24
BR112017010602A2 (pt) 2017-12-26
CN107207521A (zh) 2017-09-26
BR112017010599A2 (pt) 2017-12-26
CA2968032A1 (en) 2016-05-26
EA201791074A1 (ru) 2017-10-31
WO2016079710A1 (en) 2016-05-26
AU2015348943A1 (en) 2017-06-01
KR20170083134A (ko) 2017-07-17
AU2015348941A1 (en) 2017-06-01
JP2017534663A (ja) 2017-11-24
US20180319810A1 (en) 2018-11-08
EP3221316A1 (en) 2017-09-27
SG11201703824QA (en) 2017-06-29

Similar Documents

Publication Publication Date Title
CL2017001275A1 (es) Análogos ligados de urea sustituidos como moduladores de sirtuina
PE20150887A1 (es) Compuestos de benceno sustituidos
MX2018002326A (es) Analogos novedosos de nucleosidos sustituidos en el anillo aromatico biciclico 6-6 para su uso como inhibidores de prmt5.
ECSP11011517A (es) Compuestos antivirales
DOP2016000094A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
MX2015012867A (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
UY33735A (es) Compuestos antivirales
DOP2017000013A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
ECSP13012417A (es) Derivados de ácido napht-2-ilacético para tratar sida
PE20151067A1 (es) Inhibidores de autotaxina
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
ECSP13013068A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
UY35146A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
DOP2016000194A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
MX336549B (es) Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1.
MX2017014621A (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma.
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
NI201700056A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
MX346143B (es) Ligandos del receptor ep1.
GT201200004A (es) Imidazoles fusionados y composiciones que los contienen para el tratamiento de enfermedades parasitarias, como por ejemplo malaria